Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP-HRMB: International trial in clinically high-risk medulloblastoma in patients ≥3 years
2024-510578-25-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial of temozolomide in medulloblastoma and Sonic hedgehog medulloblastoma (SHH-MB) (2 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Planned start Nov 2021; status: authorised.
02
Drugs
temozolomide
03
Conditions
medulloblastomaSonic hedgehog medulloblastoma (SHH-MB)
Beyond the preview
Go deeper on 2024-510578-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510578-25-00.